Ixekizumab
Mechanism :
Ixekizumab is a humanized monoclonal IgG4 antibody that acts against interleukin-17A and neutrolizes its pro inflamntory effects,
IL-17A is a cytokine involved in inflammatory response associated with auto-immune disorders like psoriasis. Treatment with Ixekizumab prevents release of these proinflammatory cytokines and chemokines.
Indication :
- Plaque psoriasis: For patients requiring systemic therapy or phototherapy.
Contraindications :
• Hypersensitivity reaction to the drug or its components
• Active Tuberculosis
• Clinically important active infection
• Live vaccines
• Caution advised in:
Inflammatory bowel disease
Patients undergoing surgery
Immunocompromised patients
• Crohn's disease, inflammatory bowel disease
• Ulcerative colitis
• Hepatitis infection
• Fungal and Viral infection
• Immunosuppression
Dosing :
Available as subcutaneous injection of solution 80 mg/ml.
<6 years:
Safety and efficacy not established
≥6 years old:
<25 kg:
40 mg SC in the initial week, followed by 20 mg SC every 4 weeks.
25 to 50 kg:
80 mg SC in the initial week, followed by 40 mg every 4 weeks.
>50 kg:
160 mg SC (given as two 80mg injections), followed by 80 mg every 4 weeks.
Adverse Effect :
Serious Reactions
• Anaphylaxis
• Hypersentivity reactions
• Neutropenia
• Thrombocytopenia
• Inflammatory bowel disease
• Angioedema
• Influenza
• Ocular infection
Common Reactions
• Influenza
• Injection site reactions
• Oral candidiasis
• Urticaria
• Conjunctivtis
• Tinea
• URTI
• Nausea
Interaction :
Contraindicated
• Live vaccines
Caution advised with narrow therapeutic index drugs
Caution advised with concomitant use of other biologic agents due to risk of immunosuppresion and risk of severe infection:
• Abatacept, Canakizumab, Tofacitinib, Upadacatinib, Natalizumab, Abrocitinib, Belimumab, Infliximab, Golimumab
Hepatic Dose :
No specific guidelines available